Premed · Premed · Immunology
Lecture 18: B Cell Development and Activation
Immunology
Learning Objectives
By the end of this lecture, students will be able to:
- Describe the stages of B cell development in the bone marrow
- Explain the checkpoints for B cell selection and tolerance mechanisms
- Outline the process of B cell activation by T-dependent and T-independent antigens
- Describe the signaling events downstream of the B cell receptor (BCR)
- Distinguish between follicular, marginal zone, and B-1 B cell subsets
Lecture Content
I. Overview of B Cell Development
B cells develop from hematopoietic stem cells in the bone marrow (or in the fetal liver during prenatal life). Development proceeds through ordered stages defined by the status of immunoglobulin gene rearrangement and surface marker expression, progressing from hematopoietic stem cell to common lymphoid progenitor (CLP) to pro-B cell, pre-B cell, immature B cell, transitional B cell, and finally mature naive B cell.
Several transcription factors drive commitment to the B cell lineage. E2A (E12/E47) initiates the B cell gene program, EBF1 (early B cell factor) activates B cell-specific genes, and PAX5 commits progenitors irreversibly to the B cell lineage by repressing alternative developmental fates. Throughout early development, stromal cell interactions in the bone marrow are essential: IL-7 from stromal cells is critical for pro-B and pre-B cell survival and proliferation, SCF (stem cell factor) and CXCL12 provide survival signals, and direct cell-cell contact through adhesion molecules (VLA-4/VCAM-1) supports the developing B cells.
II. Stages of B Cell Development in Detail
During the pro-B cell stage, heavy chain gene rearrangement begins. D-J rearrangement occurs first on both chromosomes, followed by V-DJ rearrangement on one chromosome; if the first attempt is nonproductive, the second allele is tried. RAG1 and RAG2 are essential for V(D)J recombination at this stage, and TdT (terminal deoxynucleotidyl transferase) is active, adding N-nucleotides at the junctions to increase diversity. Pro-B cells express CD19, CD10, and CD34 but no surface immunoglobulin.
The pre-B cell stage is reached when a productive heavy chain rearrangement yields a mu (IgM) heavy chain protein. This mu chain pairs with the surrogate light chain (composed of VpreB and lambda-5) to form the pre-BCR, which associates with Igalpha/Igbeta signaling molecules. The pre-BCR checkpoint is a critical quality-control step: signaling from the pre-BCR confirms that a functional heavy chain has been produced, triggers allelic exclusion (shutting off RAG expression at the heavy chain locus so only one heavy chain is used), and drives a burst of proliferative expansion (large pre-B cells). After this expansion, the cells become small pre-B cells and initiate light chain rearrangement, attempting kappa first and then lambda if kappa is nonproductive. Successful light chain production displaces the surrogate light chain, yielding a complete IgM molecule on the surface.
At the immature B cell stage, the cell expresses surface IgM (monomeric, membrane-bound) and faces the central tolerance checkpoint. Cells that bind self-antigens strongly face one of three fates: clonal deletion (apoptosis of strongly self-reactive cells), receptor editing (re-expression of RAG genes to rearrange a new light chain and change specificity), or anergy (if the self-antigen is soluble or of low valency, the cell survives but becomes functionally unresponsive with reduced surface IgM). Receptor editing is the primary tolerance mechanism at this stage, with an estimated 25 to 50 percent of developing B cells undergoing editing. Non-self-reactive immature B cells are permitted to exit to the periphery.
<image>A multi-panel diagram of B cell development in the bone marrow. From left to right, the stages are: HSC → CLP → pro-B cell → large pre-B cell → small pre-B cell → immature B cell. Each stage shows the status of immunoglobulin gene rearrangement (germline, D-J rearranged, V-DJ rearranged for heavy chain; germline then V-J rearranged for light chain). Surface markers at each stage are listed (CD34, CD19, CD10, CD20, surface IgM). The pro-B cell shows RAG1/RAG2 and TdT activity. The pre-B cell shows the pre-BCR complex (mu heavy chain + surrogate light chain VpreB/lambda5 + Igalpha/Igbeta). The immature B cell shows surface IgM. Arrows indicate checkpoints: pre-BCR checkpoint (productive heavy chain?) and central tolerance checkpoint (self-reactive?). Cells failing checkpoints are marked with X (apoptosis) or curved arrows (receptor editing).</image>
III. Peripheral B Cell Maturation
Immature B cells exit the bone marrow as transitional B cells (T1, T2, and T3) and arrive in the spleen for further selection. T1 B cells (IgM-high, IgD-low) remain susceptible to tolerance mechanisms, while T2 B cells (IgM-high, IgD-high) begin acquiring survival signals. BAFF (B cell activating factor, also called BLyS) is critically important for transitional and mature B cell survival: BAFF binds its receptor BAFF-R on B cells, activating NF-kappa-B and driving anti-apoptotic gene expression. Overexpression of BAFF leads to autoimmunity by allowing excess self-reactive B cells to survive.
Mature naive B cells co-express IgM and IgD on their surface, produced by alternative splicing of the same VDJ exon to either the C-mu or C-delta constant region gene. Three major subsets of mature B cells populate the periphery. Follicular (FO) B cells constitute the majority, recirculating through the follicles of lymph nodes and spleen and participating in T-dependent responses that give rise to germinal center reactions. Marginal zone (MZ) B cells reside in the splenic marginal zone and respond rapidly to blood-borne antigens through T-independent mechanisms, producing early IgM with a pre-diversified BCR repertoire. B-1 B cells, found primarily in the peritoneal and pleural cavities, are self-renewing and produce natural antibodies (polyreactive IgM) that recognize common microbial motifs in a T-independent fashion.
IV. B Cell Activation: T-Dependent Responses
T-dependent (TD) antigens are protein antigens that require CD4+ T cell help for full B cell activation. The process begins with antigen recognition and BCR signaling. The BCR (surface immunoglobulin associated with Igalpha/Igbeta) binds antigen, and cross-linking by multivalent antigen triggers a signaling cascade: Igalpha/Igbeta ITAMs are phosphorylated by the Src family kinase Lyn, Syk kinase is recruited and activated, and downstream pathways are engaged -- PLC-gamma-2 activation (producing IP3 for calcium flux and DAG for PKC activation), the PI3K-Akt pathway (survival), and the Ras/MAPK pathway (proliferation). Signaling is dramatically amplified by the BCR co-receptor complex (CD19/CD21/CD81): CD21 (complement receptor 2, CR2) binds C3d-tagged antigen, and co-ligation of the BCR and co-receptor enhances signaling by 1,000 to 10,000-fold.
In the second step, the B cell internalizes the BCR-bound antigen by receptor-mediated endocytosis, processes it into peptides, loads them onto MHC class II, and presents the peptide-MHC II complex to a cognate CD4+ T helper cell that has been pre-activated by a DC presenting the same antigen. This T-B cell interaction, occurring at the T cell zone-follicle border in secondary lymphoid organs, involves several critical receptor-ligand pairs. The most essential is CD40L (CD154) on the Th cell binding CD40 on the B cell, which activates NF-kappa-B in the B cell and promotes survival, proliferation, isotype switching, and germinal center formation. TCR recognition of the peptide-MHC II complex provides the antigen-specific signal, and additional co-stimulatory pairs (ICOS-ICOSL, OX40-OX40L) reinforce the interaction. The clinical importance of CD40L is demonstrated by Hyper-IgM syndrome, in which mutations in CD40L prevent T-B cooperation, abolishing isotype switching and germinal center formation.
<image>A detailed diagram of T-dependent B cell activation. Panel A: A B cell with BCR binds a protein antigen. The BCR complex (surface IgM + Igalpha/Igbeta) and co-receptor complex (CD19/CD21/CD81) are shown. C3d on the antigen bridges BCR and CD21 for enhanced signaling. Intracellular signaling cascade is depicted: Lyn → Syk → PLCgamma2 → IP3/DAG; PI3K → Akt; Ras → MAPK. Panel B: The B cell internalizes the antigen, processes it, and presents peptide on MHC class II. A CD4+ Th cell recognizes peptide-MHC II via TCR. Key interactions at the T-B conjugate are labeled: TCR-pMHC II, CD40L-CD40, ICOS-ICOSL. Cytokines from the Th cell (IL-4, IL-21) are shown acting on the B cell. Panel C: Outcomes -- the activated B cell either differentiates into a short-lived plasmablast (extrafollicular response, producing early IgM) or enters the follicle to initiate a germinal center reaction.</image>
V. B Cell Activation: T-Independent Responses
T-independent (TI) antigens activate B cells without requiring CD4+ T cell help. TI-1 antigens, such as LPS and bacterial DNA, contain both a BCR epitope and an innate immune stimulus (a TLR ligand). At high concentrations they activate B cells polyclonally as mitogens, while at low concentrations they activate only antigen-specific B cells through simultaneous BCR and TLR co-engagement. TI-2 antigens, such as bacterial capsular polysaccharides and polymeric flagellin, are highly repetitive structures that extensively cross-link multiple BCRs, providing a strong activation signal without T cell help. TI-2 antigens primarily activate marginal zone and B-1 B cells.
TI responses produce mainly IgM, with limited isotype switching, no affinity maturation, and minimal immunological memory. Critically, children under 2 years of age respond poorly to TI-2 antigens because their marginal zone B cells are not yet fully developed, leaving them particularly susceptible to infections with encapsulated bacteria. This vulnerability is the rationale for conjugate vaccines, which chemically link polysaccharide antigens to carrier proteins, converting the response from T-independent to T-dependent and enabling isotype switching, affinity maturation, and memory generation in young children.
VI. Negative Regulation of B Cell Activation
Several mechanisms prevent excessive or inappropriate B cell activation. Fc-gamma-RIIB (CD32B) is an inhibitory Fc receptor on B cells: when IgG-antigen immune complexes simultaneously engage the BCR and Fc-gamma-RIIB, the ITIM signaling motif on Fc-gamma-RIIB recruits SHIP phosphatase, shutting down BCR signaling. This provides negative feedback, ensuring that high levels of IgG antibody suppress further B cell activation. CD22, which binds sialic acid-containing ligands, recruits SHP-1 phosphatase to dampen BCR signaling.
Peripheral tolerance mechanisms also restrain self-reactive B cells. Chronic BCR stimulation without T cell help induces anergy. Self-reactive B cells may be excluded from lymphoid follicles, depriving them of survival signals and leading to death by neglect. Strong self-antigen encounter in the periphery can trigger deletion through apoptosis.
<image>A comparison diagram of T-dependent versus T-independent B cell activation. Left panel (T-dependent): A protein antigen is shown being captured by BCR on a follicular B cell. The B cell processes and presents antigen to a Tfh cell. CD40L-CD40 and cytokine signals are highlighted. Outcomes include germinal center formation, isotype switching, affinity maturation, and long-lived memory. Right panel (T-independent): TI-1 antigens (LPS) shown engaging both BCR and TLR4 on a B cell simultaneously. TI-2 antigens (polysaccharide capsule) shown extensively cross-linking multiple BCRs on a marginal zone B cell. Outcomes are mainly IgM production, short-lived plasma cells, limited memory. A table below compares features: antigen type, B cell subsets involved, T cell help, isotype switching, affinity maturation, memory generation.</image>
